BIND

BIND Therapeutics, Inc. Press Releases

$6.79
*  
0.25
3.55%
Get BIND Alerts
*Delayed - data as of Jan. 30, 2015  -  Find a broker to begin trading BIND now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Woulfe Announces Completion of the Final Update to the Feasibilty Study
1/23/2015 5:00:00 PM - Market Wire


BIND Therapeutics Amends Credit Facility from Hercules Technology III, L.P. to Accelerate Accurin Pipeline Growth
1/23/2015 5:00:00 PM - Business Wire
▼-2.86 % Price Change since this news event. The Volume Ratio is 1.11.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BIND Therapeutics Co-Founder Publishes Nanotechnology Article in the Journal of the American Medical Association
1/22/2015 8:00:00 AM - Business Wire
▲3.35 % Price Change since this news event. The Volume Ratio is 0.84.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BIND Therapeutics Provides Clinical Update for BIND-014 and 2015 Strategic Overview
1/7/2015 4:00:00 PM - Business Wire
▲31.84 % Price Change since this news event. The Volume Ratio is 215.43.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gramercy Property Trust Announces Acquisition of a $7.0 Million Industrial Property in Atlanta, GA
11/26/2014 8:30:00 AM - Business Wire


BIND Therapeutics to Present at Oppenheimer 25th Annual Healthcare Conference
11/26/2014 8:30:00 AM - Business Wire


BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th EORTC-NCI-AACR Annual Symposium
11/19/2014 7:00:00 AM - Business Wire


Flagship VentureLabs™ Introduces Symbiota, Pioneer of Agricultural Innovation Through the Plant Microbiome
11/13/2014 8:30:00 AM - PR Newswire


BIND Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update
11/6/2014 7:30:00 AM - Business Wire
▼-20.58 % Price Change since this news event. The Volume Ratio is 3.3.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin™ Nanomedicines for Oncology
11/6/2014 7:25:00 AM - Business Wire
▼-20.58 % Price Change since this news event. The Volume Ratio is 3.3.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BIND Therapeutics Appoints Hagop Youssoufian, M.Sc., M.D. as Chief Medical Officer
11/4/2014 8:30:00 AM - Business Wire
▼-15.13 % Price Change since this news event. The Volume Ratio is 1.25.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day